Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

230
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
230
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Anisotropic Black Phosphorus Synaptic Device for Neuromorphic Applications.

Advanced materials (Deerfield Beach, Fla.)·2016
Same author

An accurate clone-based haplotyping method by overlapping pool sequencing.

Nucleic acids research·2016
Same author

Upregulation of proangiogenic factors expression in the synovium of temporomandibular joint condylar hyperplasia.

Oral surgery, oral medicine, oral pathology and oral radiology·2016
Same author

Synthesis and Applications of π-Extended Naphthalene Diimides.

Chemical record (New York, N.Y.)·2016
Same author

Observation of the Singly Cabibbo-Suppressed Decay D^{+}→ωπ^{+} and Evidence for D^{0}→ωπ^{0}.

Physical review letters·2016
Same author

Circular RNAs: a new frontier in the study of human diseases.

Journal of medical genetics·2016

相关实验视频

Updated: Sep 9, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.4K

通过抑制CD276表达来增强膀癌免疫疗法的纤维化降脂药物的机制

Cheng Li1, Jiahao Liu1, Long Wang1

  • 1Department of Urology, The Third Xiangya Hospital of Central South University, Changsha, 410013, China.

BMC cancer
|August 31, 2025
PubMed
概括

通过破坏线粒体功能和降低CD276的调节来抑制膀癌症的生长. 这激活了T细胞免疫力,为膀癌治疗提供了潜在的新策略.

关键词:
膀癌CD276 其他纤维酸纤维化降脂药物免疫疗法

更多相关视频

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

5.8K
A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth
06:35

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth

Published on: December 22, 2020

4.6K

相关实验视频

Last Updated: Sep 9, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.4K
Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

5.8K
A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth
06:35

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth

Published on: December 22, 2020

4.6K

科学领域:

  • 癌症学
  • 药理学
  • 免疫学

背景情况:

  • 膀癌仍然是一个严重的健康问题,治疗选择有限.
  • 降脂药物,特别是纤维化药物,已经显示出在癌症治疗中重新使用的潜力.
  • 了解纤维素诱导的抗瘤作用的分子机制对于治疗发展至关重要.

研究的目的:

  • 研究纤维化药物对膀癌细胞的增长抑制作用.
  • 阐明费诺纤维酸 (FNF) 具有抗瘤作用的机制,重点关注线粒体功能,AMPK/mTOR信号传递和CD276.
  • 评估FNF作为膀癌治疗策略的潜力.

主要方法:

  • 细胞活力测试 (CCK-8) 和MB49细胞上的IC50测定.
  • 线粒体功能测定 (呼吸链活性,ATP/ADP比率,ROS,膜潜力) 以评估FNF的影响.
  • 分析AMPK/ mTOR途径和CD276表达的西斑,免疫光和抑制剂研究.
  • 测试T细胞毒性和细胞因子分析,以评估FNF对抗瘤免疫力的影响.
  • 在体内外移植模型和安全性评估 (肝指数) 以验证FNF的有效性和安全性.

主要成果:

  • 费诺纤维酸 (FNF) 显示出显著的度依赖的MB49细胞生长抑制,具有强大的IC50.
  • FNF抑制了线粒体复合体I,诱导了氧化应激,并损坏了线粒体膜.
  • FNF激活了AMPK/ mTOR通路并降低了CD276,从而增强了T细胞介导的细胞毒性和细胞因子分泌 (IFN-γ,TNF-α).
  • 与抗CD276治疗相比,FNF表现出优异的瘤抑制,没有显著的毒性.

结论:

  • 通过向线粒体复合体I-AMPK/mTOR-CD276轴,酸 (FNF) 在膀癌中具有抗瘤作用.
  • 诱导线粒体功能障碍并降低CD276,从而增强T细胞介导的抗瘤免疫力.
  • 这项研究强调纤维酸作为一种潜在的药物重新定位策略,并确定CD276为膀癌免疫治疗的新目标.